新华制药
(000756)
| 流通市值：71.49亿 | | | 总市值：99.83亿 |
| 流通股本：4.99亿 | | | 总股本：6.97亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 4,357,548,611.17 | 2,423,049,619.1 | 8,754,721,987.78 | 6,762,620,901.32 |
| 营业总成本 | 4,159,524,749.7 | 2,313,460,629.83 | 8,390,212,699.23 | 6,434,132,318.5 |
| 其他经营收益 | | | | |
| 营业利润 | 175,660,137.98 | 119,032,957.94 | 363,984,851.26 | 311,801,703.75 |
| 利润总额 | 164,942,512.39 | 118,632,777.91 | 358,916,503.18 | 305,996,579.37 |
| 净利润 | 147,954,793.02 | 83,267,243.86 | 306,303,918.15 | 266,908,611.57 |
| 每股收益 | | | | |
| 其他综合收益 | -65,971,211.38 | -23,698,036.77 | 26,020,010.31 | -5,083,975.62 |
| 综合收益总额 | 81,983,581.64 | 59,569,207.09 | 332,323,928.46 | 261,824,635.95 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 4,225,457,895.22 | 4,051,810,002.71 | 4,033,472,605.46 | 3,898,783,848.79 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,865,963,423.01 | 5,017,117,949.06 | 5,152,223,162.7 | 5,194,956,279.23 |
| 资产总计 | 9,091,421,318.23 | 9,068,927,951.77 | 9,185,695,768.16 | 9,093,740,128.02 |
| 流动负债: | | | | |
| 流动负债合计 | 2,748,866,159.77 | 2,296,763,831.54 | 2,811,202,439.76 | 2,982,354,718.83 |
| 非流动负债: | | | | |
| 非流动负债合计 | 826,046,041.06 | 1,176,302,610.25 | 918,766,825.16 | 720,990,703.28 |
| 负债合计 | 3,574,912,200.83 | 3,473,066,441.79 | 3,729,969,264.92 | 3,703,345,422.11 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 5,271,254,379.55 | 5,349,787,689.69 | 5,208,753,244.52 | 5,149,027,624.51 |
| 股东权益合计 | 5,516,509,117.4 | 5,595,861,509.98 | 5,455,726,503.24 | 5,390,394,705.91 |
| 负债和股东权益合计 | 9,091,421,318.23 | 9,068,927,951.77 | 9,185,695,768.16 | 9,093,740,128.02 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 3,648,552,593.93 | 1,916,322,024.4 | 7,931,827,672.46 | 5,857,712,171.91 |
| 经营活动现金流出小计 | 3,487,936,788.93 | 2,032,874,727.49 | 7,398,098,964.72 | 5,535,713,308.94 |
| 经营活动产生的现金流量净额 | 160,615,805 | -116,552,703.09 | 533,728,707.74 | 321,998,862.97 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 958,190 | 844,700 | 12,098,525.77 | 10,724,588.29 |
| 投资活动现金流出小计 | 39,676,826.47 | 27,430,037.86 | 115,602,127.29 | 106,668,229.93 |
| 投资活动产生的现金流量净额 | -38,718,636.47 | -26,585,337.86 | -103,503,601.52 | -95,943,641.64 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 581,340,450.5 | 361,340,450.5 | 1,041,232,461 | 810,637,524.5 |
| 筹资活动现金流出小计 | 589,210,882.11 | 349,537,798.85 | 1,332,360,679.02 | 1,054,754,499.69 |
| 筹资活动产生的现金流量净额 | -7,870,431.61 | 11,802,651.65 | -291,128,218.02 | -244,116,975.19 |
| 汇率变动对现金及现金等价物的影响 | -6,873,784.58 | 2,343,164.68 | 7,237,015.53 | 6,124,226.96 |
| 现金及现金等价物净增加额 | 107,152,952.34 | -128,992,224.62 | 146,333,903.73 | -11,937,526.9 |
| 期末现金及现金等价物余额 | 1,390,361,866.13 | 1,154,216,689.17 | 1,283,208,913.79 | 1,124,937,483.16 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 107,152,952.34 | - | 146,333,903.73 | - |